• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Sodium Chloride 0.9% Intravenous Infusion BP
    / Teva

    Active Ingredient
    Sodium Chloride 0.9% w/v

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Solution for Infusion

    50, 100, 250, 500 or 1000 ml

    full basket chart


    Adults, older people, and children: Doses may be expressed in terms of mEq or mmol of sodium, mass of sodium, or mass of sodium salt (1 g NaCl = 394 mg, 17.1 mEq or 17.1 mmol of Na and Cl).
    The dosage, rate and duration of administration is to be individualized as determined by several factors including age, weight, clinical condition, concomitant treatment and in particular the patient’s hydration state, clinical and laboratory response to treatment. Fluid balance and plasma electrolyte
    concentrations must be monitored during treatment.
    Recommended dosage
    The recommended dosage for treatment of isotonic extracellular dehydration and sodium depletion is:
    – for adults : 500 ml to 3 liters/24h.
    – for babies and children: 20 to 100 ml per 24 h and per kg of body weight, depending on the age and the total body mass.
    The recommended dosage when used as a vehicle or diluent ranges from 50 to 250 ml per dose of medicinal product to be administered.
    When Sodium Chloride 0.9% is used as a diluent for injectable preparations of other drugs, the dosage and the infusion rate will also be dictated by the nature and the dose regimen of the prescribed drug.
    Method of administration: The solution is for administration by intravenous infusion through a sterile and non-pyrogenic administration set, using aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.
    The product should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless solution is clear, free from visible particles and the seal is intact.
    Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the solution. Administer immediately following the insertion of infusion set.
    Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
    Additives may be introduced before infusion or during infusion through the injection site.


    Treatment of isotonic extracellular dehydration. Treatment of sodium depletion. Vehicle or diluent of compatible drugs for parenteral administration.


    Hypernatremia, hyperchloremia. The contraindications related to the added medicinal product should be considered.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be increased during administration of Sodium Chloride 0.9%. Administration of Sodium Chloride 0.9% may result in decreased lithium levels.
    Corticoids/Steroids and carbenoxolone, are associated with the retention of sodium and water (with oedema and hypertension).

    Baxter Healthcare Ltd., UK